Miller E C, Kadlubar F F, Miller J A, Pitot H C, Drinkwater N R
Cancer Res. 1979 Sep;39(9):3411-8.
The carcinogenicities for rats and mice of N-methyl-4-aminoazobenzene (MAB) and its hepatic microsomal metabolite N-hydroxy-N-methyl-4-aminoazobenzene (N-hydroxy-MAB) were compared under several conditions. N-Ethyl-4-aminoazobenzene, 4-aminoazobenzene, and their N-hydroxy derivatives were also included in some of the assays. About 25% of the rats given MAB or N-hydroxy-MAB (3 to 5 mmol/kg body weight) by stomach tube over a 5-week period developed hepatic tumors by 18 to 22 months. Similarly treated rats subsequently given phenobarbital in the drinking water until the termination of the experiment developed about twice as many hepatic tumors. N-Hydroxy-MAB, administered p.o., but not MAB, also induced multiple papillomas and extensive carcinomas of the forestomach in approximately 50% of the rats. Only low incidence of hepatocellular carcinomas occurred in partially hepatectomized rats given a single i.p. injection of 180 mumol/kg body weight of MAB or N-hydroxy-MAB with or without subsequent administration of phenobarbital. Although repeated s.c. doses of N-benzoyloxy-N-methyl-4-aminoazobenzene induced sarcomas at the injection site in 90% of the rats, only 3 of 20 rats developed sarcomas at the site of s.c. injections of N-hydroxy-MAB. N-Ethyl-4-aminoazobenzene, 4-aminoazobenzene, and their N-hydroxy derivatives did not induce significant numbers of tumors in any of the above assay systems. Administration to preweaning male mice of MAB, N-hydroxy-MAB, N-hydroxy-N-ethyl-4-aminoazobenzene, and N-hydroxy-4-aminoazobenzene resulted in high incidences and high multiplicities of hepatic tumors (averages of 5 to 7 tumors/mouse) within 1 year. N-Ethyl-4-aminoazobenzene and 4-aminoazobenzene also induced hepatic tumors under the same conditions, but they were less active. These data support the conclusion that the N-hydroxy metabolites of these aminoazo dyes are proximate carcinogens.
在几种条件下比较了N-甲基-4-氨基偶氮苯(MAB)及其肝微粒体代谢产物N-羟基-N-甲基-4-氨基偶氮苯(N-羟基-MAB)对大鼠和小鼠的致癌性。某些试验中还包括N-乙基-4-氨基偶氮苯、4-氨基偶氮苯及其N-羟基衍生物。在5周内通过胃管给予MAB或N-羟基-MAB(3至5 mmol/kg体重)的大鼠中,约25%在18至22个月时发生肝肿瘤。随后在饮用水中给予苯巴比妥直至实验结束的同样处理的大鼠发生的肝肿瘤数量约为前者的两倍。经口服给予N-羟基-MAB(而非MAB)也在约50%的大鼠中诱发了多个前胃乳头状瘤和广泛的癌。在部分肝切除的大鼠中,单次腹腔注射180 μmol/kg体重的MAB或N-羟基-MAB,无论是否随后给予苯巴比妥,肝细胞癌的发生率都很低。尽管重复皮下注射N-苯甲酰氧基-N-甲基-4-氨基偶氮苯在90%的大鼠注射部位诱发了肉瘤,但20只大鼠中只有3只在皮下注射N-羟基-MAB的部位发生了肉瘤。N-乙基-4-氨基偶氮苯、4-氨基偶氮苯及其N-羟基衍生物在上述任何试验系统中均未诱发大量肿瘤。对断奶前雄性小鼠给予MAB、N-羟基-MAB、N-羟基-N-乙基-4-氨基偶氮苯和N-羟基-4-氨基偶氮苯,在1年内导致肝肿瘤的高发生率和高多发性(平均每只小鼠5至7个肿瘤)。N-乙基-4-氨基偶氮苯和4-氨基偶氮苯在相同条件下也诱发了肝肿瘤,但活性较低。这些数据支持了这些氨基偶氮染料的N-羟基代谢产物是近致癌物的结论。